Abstract | INTRODUCTION: This was the first study conducted to evaluate the efficacy of 2 oral doses of the human rotavirus vaccine, RIX4414 in Singaporean infants during the first 3 years of life. MATERIALS AND METHODS: Healthy infants, 11 to 17 weeks of age were enrolled in this randomised (1:1), double-blinded, placebo-controlled study to receive 2 oral doses of RIX4414 vaccine/placebo following a 0-, 1-month schedule. Vaccine efficacy against severe rotavirus (RV) gastroenteritis (Vesikari score ≥11) caused by wild-type RV strains from a period starting from 2 weeks post-Dose 2 until 2 and 3 years of age was calculated with 95% confidence interval (CI). Immunogenicity and safety of the vaccine were also assessed. RESULTS: Of 6542 infants enrolled, 6466 were included in the efficacy analysis and a subset of 100 infants was included in the immunogenicity analysis. Fewer severe RV gastroenteritis episodes were reported in the RIX4414 group when compared to placebo at both 2 and 3 year follow-up periods. Vaccine efficacy against severe RV gastroenteritis at the respective time points were 93.8% (95% CI, 59.9 to 99.9) and 95.2% (95% CI, 70.5 to 99.9). One to 2 months post-Dose 2 of RIX4414, 97.5% (95% CI, 86.8 to 99.9) of infants seroconverted for anti-RV IgA antibodies. The number of serious adverse events recorded from Dose 1 until 3 years of age was similar in both groups. CONCLUSION: Two oral doses of RIX4414 vaccine was immunogenic and provided high level of protection against severe RV gastroenteritis in Singaporean children, during the first 3 years of life when the disease burden is highest.
|
Authors | Kong Boo Phua, Fong Seng Lim, Seng Hock Quak, Bee Wah Lee, Yee Leong Teoh, Pemmaraju V Suryakiran, Htay Htay Han, Hans L Bock |
Journal | Annals of the Academy of Medicine, Singapore
(Ann Acad Med Singap)
Vol. 45
Issue 2
Pg. 44-50
(Feb 2016)
ISSN: 0304-4602 [Print] Singapore |
PMID | 27125345
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Viral
- Immunoglobulin A
- RIX4414 vaccine
- Rotavirus Vaccines
- Vaccines, Attenuated
|
Topics |
- Antibodies, Viral
(immunology)
- Double-Blind Method
- Female
- Gastroenteritis
(prevention & control, virology)
- Humans
- Immunogenicity, Vaccine
- Immunoglobulin A
(immunology)
- Infant
- Male
- Rotavirus
(immunology)
- Rotavirus Infections
(prevention & control)
- Rotavirus Vaccines
(immunology, therapeutic use)
- Singapore
- Treatment Outcome
- Vaccines, Attenuated
(immunology, therapeutic use)
|